There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and Arcellx Inc (ACLX – Research Report) with bullish sentiments.
BridgeBio Pharma (BBIO)
Bank of America Securities analyst Greg Harrison maintained a Buy rating on BridgeBio Pharma today and set a price target of $18.00. The company’s shares closed last Friday at $15.01.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of 4.6% and a 42.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Rocket Pharmaceuticals, and Liquidia Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $29.57 average price target, representing an 89.2% upside. In a report issued on June 7, Mizuho Securities also maintained a Buy rating on the stock with a $29.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Arcellx Inc (ACLX)
In a report released today, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Arcellx Inc, with a price target of $50.00. The company’s shares closed last Friday at $35.80.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of -1.3% and a 43.9% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Bausch Health Companies, and Tarsus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $51.40 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BBIO: